You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
I’ve been loving the satire on the “In Preparation” Substack, which includes fake articles like “Nobel Laureate Jennifer Doudna Leaves Science For Trade School, Tells Postdocs ‘Learn Welding While You Can.’”
I’ll be in San Francisco May 18 – 20 for the STAT Breakthrough West Summit. Even if you can’t make it to our very cool event, let me know if you want to meet up and talk AI or data, have a cool lab to show me, or just want to grab some ice cream:
Continue to STAT+ to read the full story…
Related articles
Supreme Court Blocks Restrictions on Abortion Pill Mifepristone, Ensuring Continued Access
WASHINGTON — The Supreme Court on Thursday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restri...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
Who Will Lead the FDA Next? The Search for a New Commissioner Heats Up
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Why Major Digital Health Companies Are Absent from Medicare’s Chronic Care Pilot Program
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it deli...
Three Years of Declining Overdose Deaths: Cautious Optimism and Lingering Concerns
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. STAT’s Helen Branswel...
Regenxbio’s Duchenne Gene Therapy Shows Success in Trial, FDA Submission Next
Regenxbio said Thursday that its experimental gene therapy for Duchenne muscular dystrophy produced sufficiently high levels of a miniaturized muscle...
CREATE Medicines Secures $122M to Advance CAR-T Therapies for Solid Tumors and Autoimmune Diseases
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. Up u...